Source:
Source:
Source:Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cell Therapy
Cost of a Stem Cell Therapy? An Estimated $512,000
Posted: June 30, 2013 at 3:01 am
The likely costs of potential stem cell therapies
and cures receive almost no attention in the media as well as
publicly from scientists and the biotech firms.
and cures receive almost no attention in the media as well as
publicly from scientists and the biotech firms.
Usually any public discussion is
obliquely framed in the context of “reimbursement,” as if
industry is owed something instead of making a business decision
about what will make a profit. Euphemisms and jargon cloak unpleasant realities such as astronomical patient costs. But what reimbursement really involves are, in fact, pricing decisions and profit margins along with
lobbying campaigns for inclusion of
therapies in normal coverage of health insurance and Medicare.
obliquely framed in the context of “reimbursement,” as if
industry is owed something instead of making a business decision
about what will make a profit. Euphemisms and jargon cloak unpleasant realities such as astronomical patient costs. But what reimbursement really involves are, in fact, pricing decisions and profit margins along with
lobbying campaigns for inclusion of
therapies in normal coverage of health insurance and Medicare.
And today a singular figure – $512,000
for one stem cell treatment – appeared in the Wall Street
Journal . The story by Kosaku Narioka and Phred Dvorak dealt
with what would be the first-ever human study of a treatment that
uses reprogrammed adult stem cells.
for one stem cell treatment – appeared in the Wall Street
Journal . The story by Kosaku Narioka and Phred Dvorak dealt
with what would be the first-ever human study of a treatment that
uses reprogrammed adult stem cells.
They reported that the study received
preliminary approval on Wednesday from a key panel of the Japan
Health Ministry. The treatment involves a form of age-related macular
degeneration, which has also been targeted by the California stem
cell agency with different approaches.
preliminary approval on Wednesday from a key panel of the Japan
Health Ministry. The treatment involves a form of age-related macular
degeneration, which has also been targeted by the California stem
cell agency with different approaches.
Buried deep in the Wall Street Journal
article, with little other discussion, was this sentence:
article, with little other discussion, was this sentence:
“One eventual obstacle, even if tests
go well, could be cost: (Masayuki) Yamato (of Tokyo Women's Medical
University) says initial estimates for the treatment run around ¥50
million ($512,000) per person."
The subject of costs for potential stem
cell treatments has rattled around in the background for years
without much deep public discussion. One reason is that high costs of
treatments are controversial and can trigger emotional debate.
Another reason is that it is very early in the therapy development
process and estimates are not likely to be entirely reliable.
cell treatments has rattled around in the background for years
without much deep public discussion. One reason is that high costs of
treatments are controversial and can trigger emotional debate.
Another reason is that it is very early in the therapy development
process and estimates are not likely to be entirely reliable.
A few years ago, however, the California stem
cell agency commissioned a study involving costs of stem cell therapies. The UC Berkeley report said,
cell agency commissioned a study involving costs of stem cell therapies. The UC Berkeley report said,
“The cost impact of the therapy is
likely to be high, because of a therapy’s high cost per patient,
and the potentially large number of individuals who might benefit
from the therapy. This expense would put additional stress on
the Medicare and Medicaid budgets, cause private
insurance health premiums to increase, and create an incentive for
private plans to avoid covering individuals eligible for a therapy.”
The findings did not seem to be exactly
welcomed. The agency sat on the 2009 study for seven months until it
was uncovered by the California Stem Cell Report in April 2010. Then
the agency was careful to say that the study did not reflect the view
of CIRM management or board leadership.
welcomed. The agency sat on the 2009 study for seven months until it
was uncovered by the California Stem Cell Report in April 2010. Then
the agency was careful to say that the study did not reflect the view
of CIRM management or board leadership.
Their wariness of being out in front on the issue could be well-advised. The pharmaceutical industry received some unpleasant attention this spring when more than 100 influential cancer specialists from more than 15 countries publicly denounced the cost of cancer drugs that exceed more than $100,000 a year.
Nonetheless pricing is critical
to both patient accessibility and therapy development. If companies
cannot make a profit on a possible therapy, it is virtually certain
not to appear in the marketplace.
to both patient accessibility and therapy development. If companies
cannot make a profit on a possible therapy, it is virtually certain
not to appear in the marketplace.
While the subject remains in the
background, it does not mean there is a lack of interest. The copy of
the Berkeley stem cell cost study that was posted online by the California
Stem Cell Report has been read 11,701 times since it was made
available in April 2010 on scribd.com.
background, it does not mean there is a lack of interest. The copy of
the Berkeley stem cell cost study that was posted online by the California
Stem Cell Report has been read 11,701 times since it was made
available in April 2010 on scribd.com.
A copy of the study can be found below.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Cost of a Stem Cell Therapy? An Estimated $512,000
Bluebird and Banking: Media Pluses for California Stem Cell Agency
Posted: June 30, 2013 at 3:01 am
The California stem cell agency scored
a couple of favorable publicity points last week as the result of a
successful stock offering by an award recipient and another piece
about creation of a stem cell bank in Northern California.
a couple of favorable publicity points last week as the result of a
successful stock offering by an award recipient and another piece
about creation of a stem cell bank in Northern California.
The IPO by bluebird bio (the company's
preferred spelling) of Massachusetts was a big winner for the
company, raising millions of dollars more than anticipated.
preferred spelling) of Massachusetts was a big winner for the
company, raising millions of dollars more than anticipated.
The Boston Globe wrote,
“Shares of the Cambridge life
sciences company bluebird bio Inc. soared almost 60 percent on their
first day of trading (last) Wednesday, an impressive debut for a
business that endured years of stagnation and another encouraging
sign for the biotechnology industry.
“The local gene therapy company
raised $101 million in an initial public offering priced at $17 per
share, higher than the $14 to $16 estimated by investment bankers.
Bluebird shares closed at $26.91 per share on Wednesday.”
The stock continues to trade around $25
a share at the time of this writing, which is good news generally for
the biotech industry.
a share at the time of this writing, which is good news generally for
the biotech industry.
The company received a $9.4 million
award last fall from the $3 billion stem cell agency. The company has yet to receive any actual cash from the agency as both parties work
out final details of an agreement, a spokesman for the agency said
last week.
award last fall from the $3 billion stem cell agency. The company has yet to receive any actual cash from the agency as both parties work
out final details of an agreement, a spokesman for the agency said
last week.
The stem cell agency touted the
successful IPO in a blog item by that said,
successful IPO in a blog item by that said,
“Bluebird Bio, one of the oldest
companies in the struggling gene therapy field, is having an
outstanding first day in the stock market today, and largely by
marrying its gene therapy technology with stem cell science. The
company’s financial milestone brings hope and excitement to both
fields.”
However, the news stories about the IPO
failed to mention the stem cell agency's involvement, which would
have been nice for the agency but was to be expected given the way
news is covered.
failed to mention the stem cell agency's involvement, which would
have been nice for the agency but was to be expected given the way
news is covered.
The story about the stem cell bank
appeared on Xconomy, an Internet news service dealing with
technology. Written by Bernadette Tansey, a former San Francisco
Chronicle reporter, the piece dealt with the both business and science of stem cell banking. She wrote,
appeared on Xconomy, an Internet news service dealing with
technology. Written by Bernadette Tansey, a former San Francisco
Chronicle reporter, the piece dealt with the both business and science of stem cell banking. She wrote,
“One of the main goals of
California’s $3 billion stem cell research agency is to draw
companies into the state so they can vie for a share of the funding.
"With a recently funded $32 million
initiative, the California
Institute for Regenerative Medicine(CIRM) has attracted two of
the biggest US players in stem cell banking to Novato, CA, to form
one of the largest biobanks of induced pluripotent stem cells (iPS
cells) in the world.”
The stem cell bank effort has become a
minor staple in recent news coverage of CIRM, surfacing in a number
of articles since the awards were approved. One of the reasons for that is that the project has a relatively straight-forward story line compared to many research efforts and the concept of "banking" is familiar to editors, writers and readers.
minor staple in recent news coverage of CIRM, surfacing in a number
of articles since the awards were approved. One of the reasons for that is that the project has a relatively straight-forward story line compared to many research efforts and the concept of "banking" is familiar to editors, writers and readers.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Bluebird and Banking: Media Pluses for California Stem Cell Agency
Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy – Video
Posted: June 29, 2013 at 10:47 am
Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy
MANILA - Punto por Punto host Anthony Taberna discusses the possible dangers of illegal stem cell therapy.
By: TheABSCBNNews
See more here:
Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy - Video
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy – Video
63 year old stroke victim was greatly improved through stem cell therapy – Video
Posted: June 29, 2013 at 10:47 am
63 year old stroke victim was greatly improved through stem cell therapy
By: Gökhan Akdo #287;an
Read more:
63 year old stroke victim was greatly improved through stem cell therapy - Video
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on 63 year old stroke victim was greatly improved through stem cell therapy – Video
Foreign doctors behind illegal stem cell therapy – Video
Posted: June 29, 2013 at 10:47 am
Foreign doctors behind illegal stem cell therapy
The Philippine Medical Association wants to go after foreign doctors who are reportedly conducting unauthorized stem cell procedures in the country.
By: TheABSCBNNews
Excerpt from:
Foreign doctors behind illegal stem cell therapy - Video
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Foreign doctors behind illegal stem cell therapy – Video
Palace warns public on stem cell therapy
Posted: June 29, 2013 at 10:47 am
MALACAANG warned Friday the public from seeking stem cell therapy following the complaint by a government official of feeling weaker after undergoing this kind of treatment.
In a press briefing, deputy presidential spokesperson Abigail Valte said that the Department of Health (DOH) will issue an administrative order regarding the stem cell treatments in the country.
"The DOH received several reports regarding the stand-alone clinics which are offering (stem cell therapies) for skin rejuvenation to make you look younger. That's why the DOH has already acted on it. It just happened that there was an incident that was highlighted," she said.
Dangerous Drugs Board chairman Antonio Villar has admitted of undergoing recently stem cell therapy in an upscale hotel in Makati City in the hope to cure bone pains. He claimed of spending around P900,000 for the treatment. But he said he only felt weaker after the therapy.
Valte said that the public should be aware that stem cell therapies are only being undertaken in the DOH-accredited hospitals and not in any hotel or stand-alone clinics.
She also said that those being accredited are the hospitals and not the doctors.
"Come August 31, hospitals should file their accreditation requirements for them to continue to offer this treatment, if they offer that (treatment). So there's an accreditation process," she explained.
Valte said that she was also told that stem cell treatment is geared toward a certain purpose and not "cure all" ailments.
There are also certain sources that are only allowed by the DOH, in particular, the Food and Drug Administration, she said.
The official also urged the public to inform the authorities of any establishments or medical practitioners who have been violating the law.
The rest is here:
Palace warns public on stem cell therapy
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Palace warns public on stem cell therapy
FDA urges hotels to guard vs stem cell therapy
Posted: June 29, 2013 at 10:47 am
By: Jet Villa, InterAksyon.com June 29, 2013 6:55 PM
InterAksyon.com The online news portal of TV5
MANILA, Philippines -- The Food and Drug Administration has asked hotels to guard against allowing stem cell therapy to be performed in their premises.
FDA acting director Dr. Kenneth Hartigan-Go said hotels may be held liable for guests found performing or undergoing stem cell therapy in their rooms.
Go pointed out that performing medical procedures like stem cell therapy in a non-health facility is illegal.
Under Republic Act 9711 or the Food and Drug Administration Act of 2009, violators face a fine of up to P500,000 plus closure of the establishment and jail terms.
In FDA Advisory 2013-012 issued May 15, the agency warned the pubic against "receiving unapproved stem cell preparations in non-health facilities."
"Patients who might receive stem cell preparations and therapy without prior FDA-Department of Health approval run the risks of contracting infectious diseases and severe complications which may lead to permanent disabilities, physical deformities, serious iatrogenic harm, autoimmune diseases and worst death, and without the benefit of health insurance coverage," the advisory said.
Posted in Stem Cell Therapy
Comments Off on FDA urges hotels to guard vs stem cell therapy
Gov’t to tighten rules on stem cell therapy
Posted: June 29, 2013 at 10:47 am
By Michael Lim Ubac Philippine Daily Inquirer
Hospitals offering stem cell therapy have until Aug. 31 to seek or renew their accreditation from the Department of Health (DOH), a Palace official said Friday.
For the information of the public, the DOH is accrediting hospitals for this kind of treatment, and come Aug. 31, these hospitals should file their accreditation requirements (with DOH) for them to continue to offer this treatment, said deputy presidential spokesperson Abigail Valte.
The government is eyeing stricter regulation of hospitals offering stem cell therapy amid speculations that the recent deaths of three politicians were due to the xenogenic (animal-based stem cell) treatment they had received in Germany last year.
Dr. Leo Olarte, president of the Philippine Medical Association (PMA) and spokesperson of the Philippine Society for Stem Cell Medicine, said the groups were still trying to determine whether the politicians had died due to their illness or due to hypersensitivity reaction from the xenogenic stem cells.
Last week, the PMA also warned of a possible scam involving German doctors coming over to perform stem cell therapy on patients in five-star hotels at around P1 million per shot.
Valte echoed a similar warning from the DOH against doctors offering the procedure in their clinics, saying that hospitals, not (individual) doctors, nor stand-alone clinics, are the ones being accredited.
Not a cure all
The Palace official also cautioned the public against claims that stem cell therapy was a cure all (for diseases).
There is no treatment that will cure all of your ills. Much less your love problems, Valte said.
Posted in Stem Cell Therapy
Comments Off on Gov’t to tighten rules on stem cell therapy
Stem Cell Therapy Becomes More Widely Available | Video ABC News – Video
Posted: June 28, 2013 at 12:48 pm
Stem Cell Therapy Becomes More Widely Available | Video ABC News
Beverly Hills Orthopedic surgeon Dr. Raj appeared on ABC #39;s Good Morning America to share the breatkthrough stem cell treatment that #39;s now available to weeken...
By: AHPRvideo
Read more:
Stem Cell Therapy Becomes More Widely Available | Video ABC News - Video
Posted in Stem Cell Therapy
Comments Off on Stem Cell Therapy Becomes More Widely Available | Video ABC News – Video
Cost of a Stem Cell Therapy? An Estimated $512,000
Posted: June 28, 2013 at 12:12 pm
The likely costs of potential stem cell therapies
and cures receive almost no attention in the media as well as
publicly from scientists and the biotech firms.
and cures receive almost no attention in the media as well as
publicly from scientists and the biotech firms.
Usually any public discussion is
obliquely framed in the context of “reimbursement,” as if
industry is owed something instead of making a business decision
about what will make a profit. Euphemisms and jargon cloak unpleasant realities such as astronomical patient costs. But what reimbursement really involves are, in fact, pricing decisions and profit margins along with
lobbying campaigns for inclusion of
therapies in normal coverage of health insurance and Medicare.
obliquely framed in the context of “reimbursement,” as if
industry is owed something instead of making a business decision
about what will make a profit. Euphemisms and jargon cloak unpleasant realities such as astronomical patient costs. But what reimbursement really involves are, in fact, pricing decisions and profit margins along with
lobbying campaigns for inclusion of
therapies in normal coverage of health insurance and Medicare.
And today a singular figure – $512,000
for one stem cell treatment – appeared in the Wall Street
Journal . The story by Kosaku Narioka and Phred Dvorak dealt
with what would be the first-ever human study of a treatment that
uses reprogrammed adult stem cells.
for one stem cell treatment – appeared in the Wall Street
Journal . The story by Kosaku Narioka and Phred Dvorak dealt
with what would be the first-ever human study of a treatment that
uses reprogrammed adult stem cells.
They reported that the study received
preliminary approval on Wednesday from a key panel of the Japan
Health Ministry. The treatment involves a form of age-related macular
degeneration, which has also been targeted by the California stem
cell agency with different approaches.
preliminary approval on Wednesday from a key panel of the Japan
Health Ministry. The treatment involves a form of age-related macular
degeneration, which has also been targeted by the California stem
cell agency with different approaches.
Buried deep in the Wall Street Journal
article, with little other discussion, was this sentence:
article, with little other discussion, was this sentence:
“One eventual obstacle, even if tests
go well, could be cost: (Masayuki) Yamato (of Tokyo Women's Medical
University) says initial estimates for the treatment run around ¥50
million ($512,000) per person."
The subject of costs for potential stem
cell treatments has rattled around in the background for years
without much deep public discussion. One reason is that high costs of
treatments are controversial and can trigger emotional debate.
Another reason is that it is very early in the therapy development
process and estimates are not likely to be entirely reliable.
cell treatments has rattled around in the background for years
without much deep public discussion. One reason is that high costs of
treatments are controversial and can trigger emotional debate.
Another reason is that it is very early in the therapy development
process and estimates are not likely to be entirely reliable.
A few years ago, however, the California stem
cell agency commissioned a study involving costs of stem cell therapies. The UC Berkeley report said,
cell agency commissioned a study involving costs of stem cell therapies. The UC Berkeley report said,
“The cost impact of the therapy is
likely to be high, because of a therapy’s high cost per patient,
and the potentially large number of individuals who might benefit
from the therapy. This expense would put additional stress on
the Medicare and Medicaid budgets, cause private
insurance health premiums to increase, and create an incentive for
private plans to avoid covering individuals eligible for a therapy.”
The findings did not seem to be exactly
welcomed. The agency sat on the 2009 study for seven months until it
was uncovered by the California Stem Cell Report in April 2010. Then
the agency was careful to say that the study did not reflect the view
of CIRM management or board leadership.
welcomed. The agency sat on the 2009 study for seven months until it
was uncovered by the California Stem Cell Report in April 2010. Then
the agency was careful to say that the study did not reflect the view
of CIRM management or board leadership.
Their wariness of being out in front on the issue could be well-advised. The pharmaceutical industry received some unpleasant attention this spring when more than 100 influential cancer specialists from more than 15 countries publicly denounced the cost of cancer drugs that exceed more than $100,000 a year.
Nonetheless pricing is critical
to both patient accessibility and therapy development. If companies
cannot make a profit on a possible therapy, it is virtually certain
not to appear in the marketplace.
to both patient accessibility and therapy development. If companies
cannot make a profit on a possible therapy, it is virtually certain
not to appear in the marketplace.
While the subject remains in the
background, it does not mean there is a lack of interest. The copy of
the Berkeley stem cell cost study that was posted online by the California
Stem Cell Report has been read 11,701 times since it was made
available in April 2010 on scribd.com.
background, it does not mean there is a lack of interest. The copy of
the Berkeley stem cell cost study that was posted online by the California
Stem Cell Report has been read 11,701 times since it was made
available in April 2010 on scribd.com.
A copy of the study can be found below.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Cost of a Stem Cell Therapy? An Estimated $512,000
